Optimus becomes the First Company to Conclude Study of Molnupiravir Phase 3 Clinical Trial with Promising Results
Optimus Group has announced the successful completion of the much-awaited Molnupiravir Oral…
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 21, 2025 17:05 ET | Source: Annovis Bio Inc. MALVERN, Pa.,…
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 20, 2025 17:35 ET | Source: vTv Therapeutics Inc. Clinical hold…
Nasscom Hosts Inaugural Global Confluence 2025 to Shape the Future of Technology and Global Alliances
NEW DELHI, March 20, 2025 /PRNewswire/ -- Nasscom, today, successfully hosted the first edition of the Global Confluence 2025 at Hotel Shangri-La,…
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Multi-center clinical trial includes sites located in the US, UK and EU…
Fractal Invests $20 Million in Asper.AI to Drive Next Phase of Growth and Innovation
NEW YORK and MUMBAI, India , March 19, 2025 /PRNewswire/ -- Fractal (www.fractal.ai), a…
Huawei DigiTruck Kenya Celebrates 290 New Digital Skills Graduates
HOMA BAY, Kenya, March 19, 2025 /PRNewswire/ -- Kenya DigiTruck project partners and…
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470…
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class…
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF)
Interim data and topline data readouts from Phase 2a biomarker study expected…